Moderna and Merck's individualized neoantigen therapy intismeran autogene has put personalized mRNA cancer treatment on the ...
FDA cleared Click Therapeutics’ Motivista, a smartphone adjunct for schizophrenia’s negative symptoms. Click says state ...
A range of speakers from government, regulators and the industry lay out at the BioJapan meeting in Yokohama the major ...
FDA staff said the move to allow compounding of some unapproved peptide products raises patient safety concerns and weakens ...
Results from a comparison of mifepristone's safety to surgical abortion are expected in December with a final report in March ...
Leaders in the cell therapy field talked about how to expand access to CAR-T cell therapy, with one exec saying bringing it ...
Unilever is accelerating hair care’s shift toward 'skinification,' using advances in hair science to develop products focused ...
Medical Microinstruments raised $125m in Series D funding, led by BioStar Capital. The firm will use the funds to expand ...
The company updated investors on the status of evenamide development for schizophrenia as the US FDA investigates four deaths ...
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries ...
Former US FDA advisory committee chair Eric Brass told the AESGP switch conference in Brussels that switch decisions focus ...
The successor to Emer Cooke as head of the European Medicines Agency could be identified soon, with the successful candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results